Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06183047

Enrollment

Registered

2023-12-27

Start date

2016-10-01

Completion date

2023-09-30

Last updated

2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Release of Chromogranin A (CgA)

Brief summary

The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.

Interventions

DIAGNOSTIC_TESTearly release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* confirmed NET * peptide receptor radionuclide therapy (PRRT)

Exclusion criteria

* lack of patient consent to a clinical trial

Design outcomes

Primary

Measure	Time frame	Description
The CgA level change	2016-2023	We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026